Research Article

Performance of a Novel In Vitro Assay for Skin Sensitization Based on Activation of T Lymphocytes

Fenxia Hou, Caihong Xing, Bin Li, Juan Cheng and Wei Chen

Department of Toxicology, National Institute of Occupational Health and Poison Control, Chinese Center for Disease Control and Prevention, Beijing, China

Abstract

There are currently no skin sensitization assays based on T cell activation. We built a novel in vitro test to assess T cell activation and assessed its performance to discriminate skin sensitizers from non-sensitizers using 52 reference chemicals. Jurkat Clone E6-1 human T lymphocytes were exposed to a series of concentrations of test substances for 24 hours and CD69 expression was measured as a marker of early T cell activation by flow cytometry. Most sensitizers tested induced an increased relative fluorescence intensity (RFI) of CD69 on the T cells, which was linearly correlated with the tested concentrations, indicating a statistically significant causal link between sensitizer concentration and increase of CD69 expression. CD69 RFI ≥ 1.5 was determined as the positive criterion for skin sensitizer classification when cell viability ≥ 50%. The sensitivity (79.4%), specificity (88.9%) and accuracy (82.7%) of our test for the 52 tested reference chemicals showed a good predictivity for skin sensitizers. Results were reproduced in at least two repeats, and the concurrent positive control, 2 µg/ml 2,4-dinitrochlorobenzene, was found positive in all 25 independent runs conducted, indicating in-house reproducibility. The EC1.5 value, i.e., the concentration at which a test chemical induces a CD69 RFI of 1.5, may be used to categorize skin sensitization potency of a chemical. This work may contribute to the development of an in vitro assay for skin sensitization based on the activation of T cells.

1 Introduction

Skin sensitization is one of the key adverse effects that many chemicals possess. Identifying the hazard of skin sensitization of new chemicals is demanded under health regulations worldwide. Animal assays that can be used to predict whether chemicals cause skin sensitization are the guinea pig maximization test, the Buehler test (OECD, 1992), and the murine local lymph node assay (LLNA) (OECD, 2010a,b,c). During the last decade, intensive work has been done to develop in vitro assays for skin sensitization to replace animal testing with non-animal methods (EU, 2009; Casey, 2016).

To contribute to the development of in vitro assays for skin sensitization, the adverse outcome pathway (AOP) for skin sensitization was described (OECD, 2012). The AOP contains four key events (KEs). Currently, the Organization for Economic Co-operation and Development (OECD) has developed and adopted several assays for skin sensitization based on the first three of the four AOP KEs (OECD, 2015a,b, 2018). However, the OECD has not formally adopted any in vitro assay representing the fourth KE yet. In addition, it is consistently argued that a single in vitro assay for skin sensitization is not sufficient to substitute testing in an animal model (e.g., the LLNA). Instead, combination of in vitro methods into integrated approaches to testing and assessment (IATA) will be required (Jowsey et al., 2006; Corsini et al., 2014; Reisinger et al., 2015; Ezendam et al., 2016; Jaworska, 2016; Strickland et al., 2016). The integration of information derived from assays for the first three of the four AOP KEs for the skin sensitization AOP already is the basis for several defined approaches (DA) to be used in IATA (OECD, 2016). Additional data on the fourth KE for the skin sensitization AOP may provide useful complementary information to complete the development of AOP-based DAs and IATAs and improve current predictive parameters.

The fourth KE of the AOP for skin sensitization relates to the activation of naïve T cells and proliferation of antigen-specific
effector and memory T cells (OECD, 2012). It plays a key role in the AOP. However, it represents a complex biological process. In short, two types of signal that act synergistically are required for full activation of naïve T lymphocytes. Binding of antigenic peptides to MHC molecules presented by antigen-presenting cells (APC) to T cell receptors (TCR) on the T cells provides the first signal. The second signal results from the interaction of costimulatory receptors on T cells with their ligands on the APCs. The best characterized costimulatory molecule is CD28. Its ligands are CD80 and CD86 on APCs (June et al., 1999; Robey and Allison, 1995; Chakraborty and Weiss, 2014). In addition, cytokines are essential for T cell activation. For example, IL-1α, IL-1β, IL-18 and TNF-α are needed for APCs to migrate from the epidermis to the dermis and then to the proximal lymph nodes, where they present the hapten-protein complex to T-cells; IL-2 is needed for full T cell activation (OECD, 2012). The complexity of the processes makes it difficult to perfectly model the process in vitro. A consensus report of a recent Cosmetics Europe Workshop (van Vliet et al., 2018) comprehensively discussed the state-of-the-art of the assays that have been developed to assess T cell activation by skin sensitizers. It concluded that although a number of T cell-based assays (Dietz et al., 2010; Richter et al., 2013; Vocanson et al., 2014; Ahmed et al., 2016) currently show encouraging test results in predicting the immunogenic potential of chemicals, they are time-consuming, laborious and expensive, and also have donor-to-donor variability. Further intensive research is required to solve these problems. The review indicates that it is currently difficult to anticipate the use of T cell assay data for safety assessment.

In this study, a new in vitro test to assess T cell activation by skin sensitizers is investigated to contribute to the development of in vitro assays for skin sensitization corresponding to the fourth KE. The cluster of differentiation 69 (CD69) is a glycoprotein expressed on the T cell surface triggered by TCR activation (Testi et al., 1989; Ziegler et al., 1994; Cimo et al., 2013). Expression of CD69 on the surface of T lymphocytes is considered a marker of early T cell activation (D’Ambrosio et al., 1994; Ziegler et al., 1994; Taylor-Fishwick and Siegel, 1995; Morgan et al., 1999; Green et al., 2003; Cimo et al., 2013; Dimitrova et al., 2018; Klug et al., 2019). Immune sensitization therefore could induce an increase in CD69 expression on T lymphocytes (Swiarski et al., 2002; Konrad et al., 2004; Avgustin et al., 2005; Bavandi et al., 2006; Beeler et al., 2008; Zahid et al., 2019; Korren et al., 2019).

The Jurkat Clone E6-1 human T lymphocyte is an immortal cell line often used in studies on in vitro human T cell activation (Fernández-Riejos et al., 2008; Pan et al., 2015; Ngo et al., 2017; Chen et al., 2018; Vis et al., 2018; Colin-York et al., 2019; Kim et al., 2019). It has been reported that for some chemicals that incubating them in vitro with the Jurkat T cells in culture medium induced early T cell activation manifesting as an increase in CD69 expression on the Jurkat T cells in the absence of APCs in the test system (Fernández-Riejos et al., 2008; Chen et al., 2018; Vis et al., 2018).

Based on these reports, a novel in vitro T cell-based test to predict skin sensitization of chemicals was developed. Briefly, Jurkat Clone E6-1 human T lymphocytes are exposed to test substances for 24 h and changes of CD69 expression on the T cells are determined using flow cytometry. As a proof of principle, the skin sensitizers 2,4-dinitrochlorobenzene, 4-phenylenediamine and cobalt chloride were shown to cause an increase in CD69 expression in pilot experiments. Here, we evaluated the predictive performance of the test system to identify skin sensitizers using 52 reference chemicals.

2 Materials and methods

Chemicals

A total of 52 chemicals were tested of which 34 are sensitizers and 18 are non-sensitizers. All chemicals have been evaluated in the LLNA (Ashby et al., 1993; ICCVAM, 1999, 2010; Bassketter et al., 2012; Urbisch et al., 2016), and they include many of the most commonly used reference substances for testing in vitro assays for skin sensitization (Sens-it-iv, 2009; Chipinda et al., 2011; Hennen et al., 2011; Emter et al., 2010; Nukada et al., 2012, 2013). They are listed, together with the suppliers from whom they were purchased and the concentrations tested, in Table 1. The vehicle, dimethyl sulfoxide (DMSO) (ultra-pure, product no.: N182-5×10-ML) was purchased from Amresco.

Cells and cell culture

The immortal cell line Jurkat Clone E6-1 human T lymphocyte was purchased from BeNa Culture Collection (Beijing, China). Cells were cultured in 75 mL or 100 mL culture flasks at 37°C under 5% CO2 and humidified atmosphere in RPMI 1640 supplemented with 5 mM HEPES, 2 mM L-glutamine, 10% heat-inactivated fetal bovine serum (Corning, Cellgro, New Zealand, product no.: 35-081-CV) and 1% penicillin-streptomycin (Invitrogen Corp., product no.: 15140122). The cells were seeded every 2 days at a density of 2×10^4 cells/mL. The passage numbers used for the test were between 5 and 30. The identity of the Jurkat Clone E6-1 human T lymphocyte used in this study was confirmed via the human STR profiling cell authentication service provided by BeNa Culture Collection (Beijing, China). The cells were tested negative for mycoplasma contamination by the supplier by a method of bioluminescence (luciferase) to test the enzymes specific for mycoplasma before this study was begun (Mycoplasma Detection Kit, LM009, Shanghai Yise Medical Technology Co., Ltd., Shanghai, China). All procedures for cell manipulation in this study strictly followed the good laboratory practice for sterile techniques of our laboratory.

Test concentrations and treatment of the cells

The concentrations tested for each chemical are shown in Table 1. They were selected mainly by conducting preliminary tests to determine concentrations that could induce a positive result with appropriate cell viability. The concentrations tested in the formal testing were at least three concentrations at 1.2-fold, 1.5-fold or 2-fold serial dilutions. The highest concentration for each chemical should not cause a drop in cell viability to less than 50%. The vehicle for nickel sulfate, nickel chloride, and sodium lauryl sul-
Tab. 1: The test substances and concentrations tested

| Chemicals                        | CAS number | Physical form | Supplier | Concentrations tested (µg/mL) | LLNA potency category |
|----------------------------------|------------|---------------|----------|-------------------------------|-----------------------|
| **34 sensitizers**               |            |               |          |                               |                       |
| Oxazolone **b,c**               | 15646-46-5 | S             | Alfa Aesar | 250, 200, 167, 139            | extreme               |
| 5-Chloro-2-methyl-4-isothiazolin-3-one **a,c** | 26172-55-4 | L             | Aladdin   | 1.8, 1.5, 1, 0.67, 0.44, 0.30 | extreme               |
| p-Benzquinone **c**             | 106-51-4   | S             | SCR       | 4, 3.33, 2.78, 2.31           | extreme               |
| 2,4-Dinitrochlorobenzene **a,b,c** | 97-00-7    | S             | SCR       | 2, 1.33, 0.89, 0.59, 0.40     | extreme               |
| 4-Nitrobenzyl bromide **b,c**   | 100-11-8   | S             | Aladdin   | 2.1, 0.5, 0.3, 0.25, 0.21, 0.17 | extreme               |
| Benzo[a]pyrene                  | 50-32-8    | S             | Aladdin   | 60, 50, 41.7, 34.7, 28.9, 24.1, 20.1, 16.7 | extreme               |
| Glutaraldehyde **b,c**          | 111-30-8   | L             | SCR       | 3.3, 2.2, 1.5, 1.0            | strong                |
| 4-Phenylenediamine **a,b,c**    | 106-50-3   | S             | SCR       | 5, 4.17, 3.47, 2.89, 2.41     | strong                |
| Formaldehyde **c**              | 50-00-0    | L             | SCR       | 4.8, 4.0, 3.33, 2.78, 2.31, 1.93 | strong                |
| Cobalt chloride **a,c**         | 7646-79-9  | S             | Urchem    | 80, 66.7, 55.6, 46.3, 38.6, 32.1 | strong                |
| 4-Methylaminophenol sulfate **c** | 55-55-0    | S             | TCI       | 4, 3.33, 2.78, 2.31, 1.93     | strong                |
| Tetramethylthiuram disulfide **b,c** | 137-26-8  | S             | Aladdin   | 8, 5.3, 5.417, 3.47, 2.89, 2.41 | moderate             |
| 2-Methoxy-4-methylphenol        | 93-51-6    | L             | TCI       | 200, 133, 89, 59, 40          | moderate             |
| Glyoxal **b,c**                 | 107-22-2   | L             | Aladdin   | 89, 80, 66.7, 55.6, 46.3, 38.6, 32.2 | moderate             |
| trans-Cinnamaldehyde            | 14371-10-9 | L             | SCR       | 6.5, 4.17, 3.47, 2.89         | moderate             |
| Isoeugenol **a,b,c**            | 97-54-1    | L             | TCI       | 120, 100, 83.3, 69.4, 57.9, 48.2, 40.2 | moderate             |
| 2-Mercaptobenzothiazole **a,b,c** | 49-30-4    | S             | SCR       | 150, 125, 104, 86.8, 72.3, 60.3, 50.2 | moderate             |
| Cinnamic aldehyde **b,c**       | 104-55-2   | L             | Adamas    | 7.2, 6, 5, 4.1               | moderate             |
| m-Aminophenol                   | 591-27-5   | S             | SCR       | 150, 125, 104, 87, 72, 66.7, 44.4, 29.6 | moderate             |
| Diethyl maleate                 | 141-05-9   | L             | SCR       | 40, 26.7, 17.8, 11.9, 9.87   | moderate             |
| Nickel sulfate **c**            | 7786-81-4  | S             | SCR       | 120, 80, 53.3, 35.6           | moderate             |
| Resorcinol **b,c**              | 108-46-3   | L             | SCR       | 500, 417, 347, 289, 241, 201  | moderate             |
| Nickel chloride **a**           | 7718-54-9  | S             | Aladdin   | 100, 83.3, 69.4, 57.9, 48.2   | moderate             |
| Citral **a,c**                  | 5392-40-5  | L             | SCR       | 30, 25, 20.8, 17.4, 14.5, 12.0, 10.0, 8.4 | weak                |
| Hexyl cinnamic aldehyde **a,c** | 101-86-0   | L             | TCI       | 40, 26.7, 17.8, 11.8          | weak                 |
| Eugenol **a,b,c**               | 97-53-0    | L             | TCI       | 120, 80, 53, 36               | weak                 |
| Phenyl benzoate **a,c**         | 93-99-2    | S             | TCI       | 250, 125, 62.5, 31.2          | weak                 |
| Cinnamic alcohol **a,b,c**      | 104-54-1   | L             | TCI       | 120, 100, 83.3, 69.4, 57.9, 48.2, 40.2, 33.5, 27.9 | weak                |
| Cyclamen aldehyde               | 103-95-7   | L             | SCR       | 50, 41.6, 34.7, 28.9          | weak                 |
| Hydroxycitronella **c**         | 107-75-5   | L             | SCR       | 500, 333, 222, 200, 133.3, 88.9, 59.2, 39.5, 26.3, 17.6, 11.7 | weak                |
| Imidazolidinyl urea **a,c**     | 39236-46-9 | S             | TCI       | 120, 100, 83.3, 69.4, 57.9    | weak                 |
| Linalool                        | 78-70-6    | L             | TCI       | 1000, 667, 444, 296           | weak                 |
| Ethyl acrylate                  | 140-88-5   | L             | SCR       | 444, 296, 197, 132           | weak                 |
| Methyl methacrylate **a**       | 80-62-6    | L             | Aladdin   | 5000, 4000, 3000, 2000, 1000, 833, 694, 579, 500, 250, 125, 62.5 | weak                |
buffer containing 0.01% (w/v) globulin (Cohn fraction II, III, human: SIGMA, #G2388-10G)) and incubated at 4°C for 15 min. After blocking, two 90 µL aliquots of the cells were transferred into a 96-well round-bottom plate or 180 µL into a small tube. After centrifugation, cells were stained with 25 µL (or 50 µL for small tube) of FITC (fluorescein isothiocyanate)-labelled mouse anti-human CD69 antibody (BD-PharMingen, #555530; Clone: FN50) or FITC-labelled mouse IgG1 (CD69 isotype antibody) (BD-PharMingen, #555748; Clone: MOPC-21) at 4°C for 30 min. The two antibodies were diluted 3:25 (v/v) in staining buffer. After washing three times with 150 µL staining buffer, dead cells in the samples were stained with 25 µL (or 50 µL for small tube) 7-aminoactinomycin D (7-AAD) (Abcam, #ab228563; diluted 1:25 (v/v) with staining buffer) at room temperature for 5 min. Then 150 µL (or 300 µL for small tube) staining buffer was added to each well (or each tube) to re-suspend the cells. Expression levels of CD69 and cell viability were analyzed using flow cytometry (Accuri C6, fate was complete RPMI 1640 medium. The vehicle for all other chemicals was DMSO.

The procedure for treatment of the cells was as follows: The Jurkat Clone E6-1 T lymphocytes (1×10⁶ cells/well/mL in 24-well flat-bottom plate) were incubated with the test chemicals in the given concentrations for 24 ±0.5 h. 2.0 µg/mL 2, 4-dinitrochlorobenzene (DNCB) in DMSO was the concurrent positive control in each test run. 2000 µg/mL (0.2%) DMSO was the vehicle (negative) control in each test run as well as the final concentration of DMSO in each well containing test chemical.

### Flow cytometry analysis

After exposure to the chemicals, cells were transferred from the 24-well plate into a 5mL tube (#352052, BD Falcon) and washed twice with 1.5 mL staining buffer (phosphate-buffered saline (PBS) solution containing 0.1% (w/v) bovine serum albumin). Then cells were blocked with 600 µL blocking solution (staining buffer containing 0.01% (w/v) globulin (Cohn fraction II, III, human: SIGMA, #G2388-10G)) and incubated at 4°C for 15 min. After blocking, two 90 µL aliquots of the cells were transferred into a 96-well round-bottom plate or 180 µL into a small tube. After centrifugation, cells were stained with 25 µL (or 50 µL for small tube) of FITC (fluorescein isothiocyanate)-labelled mouse anti-human CD69 antibody (BD-PharMingen, #555530; Clone: FN50) or FITC-labelled mouse IgG1 (CD69 isotype antibody) (BD-PharMingen, #555748; Clone: MOPC-21) at 4°C for 30 min. The two antibodies were diluted 3:25 (v/v) in staining buffer. After washing three times with 150 µL staining buffer, dead cells in the samples were stained with 25 µL (or 50 µL for small tube) 7-aminoactinomycin D (7-AAD) (Abcam, #ab228563; diluted 1:25 (v/v) with staining buffer) at room temperature for 5 min. Then 150 µL (or 300 µL for small tube) staining buffer was added to each well (or each tube) to re-suspend the cells. Expression levels of CD69 and cell viability were analyzed using flow cytometry (Accuri C6,
BD Biosciences) in the acquisition channels FL-1 and FL-3, respectively. A total of 10,000 living cells (7-AAD negative) were acquired. The geometric mean fluorescence intensity (MFI) was recorded and the relative fluorescence intensity (RFI) value of CD69 expression (CD69 RFI) at each concentration of test substance was calculated according to the following equation:

\[
CD69\ RFI = \frac{\text{MFI of chemical treated cells} - \text{MFI of chemical treated isotype control}}{\text{MFI of vehicle treated control cells} - \text{MFI of vehicle treated isotype control}}
\]

### 3 Results

#### 3.1 Positive criteria

When cell viability was less than 50%, the RFI was not calculated as intracellular interfering structures might be labeled due to cell membrane destruction, which could interfere with fluorescent measurement. Initially, the predictive performance at different cut-off values for CD69 RFI was assessed (Tab. 2). The best prediction accuracy (82.7%) was found when the cut-off was between 1.5 and 1.7. To ensure optimal sensitivity of the test, the lower cut-off border of 1.5 was selected as the prediction rule. Therefore, the criterion to predict CD69 expression at a specific concentration of test chemical as a positive response was set as CD69 RFI \( \geq 1.5 \) at cell viability \( \geq 50\% \).

### Tab. 2: Predictive performances for different positive criteria

| Positive criteria (CD69 RFI) | Sensitivity | Specificity | Accuracy |
|-----------------------------|-------------|-------------|-----------|
| 1.3                         | 88.2% (30/34) | 61.1% (11/18) | 78.8% (42/52) |
| 1.4                         | 85.3% (29/34) | 72.2% (13/18) | 80.8% (42/52) |
| 1.5                         | 79.4% (27/34) | 88.9% (16/18) | 82.7% (43/52) |
| 1.6                         | 79.4% (27/34) | 88.9% (16/18) | 82.7% (43/52) |
| 1.7                         | 79.4% (27/34) | 88.9% (16/18) | 82.7% (43/52) |
| 1.8                         | 76.5% (26/34) | 88.9% (16/18) | 80.8% (42/52) |
| 1.9                         | 76.5% (26/34) | 88.9% (16/18) | 80.8% (42/52) |
| 2.0                         | 76.5% (26/34) | 88.9% (16/18) | 80.8% (42/52) |
| 2.1                         | 67.6% (23/34) | 88.9% (16/18) | 75.0% (39/52) |
| 2.2                         | 58.8% (20/34) | 100% (18/18) | 73.1% (38/52) |

Altogether 52 reference substances including 34 skin sensitizers and 18 non-sensitizers were tested in this test model (see Tab. 1). A substance was judged as a sensitizer (i.e., positive response) when its maximum CD69 RFI value (see Tab. 3) exceeded the indicated positive criteria. Sensitivity: The proportion of skin sensitizers that are correctly identified as positive according to the corresponding positive criteria. Specificity: The proportion of non-sensitizers that are correctly identified as negative according to the corresponding positive criteria. Accuracy: The proportion of correct outcomes according to the corresponding positive criteria.

### Tab. 3: Results of CD69 expression induced by the 52 substances tested in our study

| Substances                          | CD69 prediction (1.5-fold) | Maximum CD69 RFI | Positive runs in total runs |
|-------------------------------------|-----------------------------|------------------|-----------------------------|
| 34 sensitizers                      |                             |                  |                             |
| Oxazolone                           | –                           | 1.22             | 0/2                         |
| 5-Chloro-2-methyl-4-isothiazolin-3-one a | –                           | 1.49             | 0/3                         |
| p-Benzochinone                      | +                           | 2.35             | 3/3                         |
| 2,4-Dinitrochlorobenzene a          | +                           | 3.51             | 25/25                       |
| 4-Nitrobenzyl bromide               | +                           | 4.01             | 2/2                         |
| Benzo[a]pyrene                      | +                           | 6.24             | 2/2                         |
| Glutaraldehyde                      | +                           | 3.26             | 2/2                         |
| 4-Phenylenediamine a                | +                           | 3.24             | 2/2                         |
| Formaldehyde                        | +                           | 2.22             | 3/3                         |
| Cobalt chloride a                   | +                           | 5.87             | 3/3                         |
| 4-Methylaminophenol sulfate         | +                           | 2.37             | 2/2                         |
| Tetramethylthiuram disulfide        | +                           | 3.23             | 2/2                         |
| 2-Methoxy-4-methylphenol            | +                           | 2.07             | 2/2                         |
| Glyoxal                             | +                           | 8.63             | 2/2                         |
| trans-Cinnamaldehyde                | +                           | 2.33             | 3/3                         |
| Isoeugenol a                        | –                           | 1.39             | 0/3                         |
| Substances                              | CD69 prediction (1.5-fold) | Maximum CD69 RFI | Positive runs in total runs |
|-----------------------------------------|----------------------------|------------------|-----------------------------|
| 2-Mercaptobenzothiazole a               | +                          | 2.04             | 2/2                         |
| Cinnamic aldehyde                       | –                          | 1.09             | 1/3                         |
| m-Aminophenol                           | +                          | 4.84             | 2/2                         |
| Diethyl maleate                         | +                          | 2.12             | 2/2                         |
| Nickel sulfate                          | +                          | 3.87             | 2/2                         |
| Resorcinol                              | +                          | 3.20             | 2/2                         |
| Nickel chloride a                       | +                          | 2.15             | 3/3                         |
| Citral a                                | –                          | 1.09             | 1/3                         |
| Hexyl cinnamic aldehyde a               | +                          | 3.34             | 2/2                         |
| Eugenol a                               | +                          | 2.36             | 2/2                         |
| Phenyl benzoate a                       | +                          | 2.10             | 2/2                         |
| Cinnamic alcohol a                      | –                          | 1.24             | 0/2                         |
| Cyclamen aldehyde                       | +                          | 1.80             | 2/2                         |
| Hydroxycitronellal                      | +                          | 17.29            | 3/3                         |
| Imidazolidinyl urea a                   | +                          | 2.04             | 2/2                         |
| Linalool                                | +                          | 2.99             | 2/2                         |
| Ethyl acrylate                          | +                          | 3.25             | 2/2                         |
| Methyl methacrylate a                   | –                          | 1.49             | 0/3                         |
| **18 non-sensitizers**                  |                            |                  |                             |
| Sodium lauryl sulfate a                 | +                          | 2.18             | 2/2                         |
| Ethylene glycol dimethacrylate a        | –                          | 1.41             | 0/3                         |
| Xylene a                                | –                          | 1.31             | 0/2                         |
| Propylparaben                           | –                          | 1.38             | 0/2                         |
| Caprylic (octanoic) acid                | –                          | 1.46             | 0/2                         |
| Benzalkonium chloride                   | –                          | 1.06             | 0/2                         |
| Chlorobenzene a                         | –                          | 1.25             | 0/2                         |
| 4-Aminobenzoic acid                     | –                          | 1.01             | 0/2                         |
| Lactic acid a                           | –                          | 1.25             | 1/3                         |
| Diethyl phthalate                       | –                          | 1.29             | 0/3                         |
| Dimethyl isophthalate                   | –                          | 0.61             | 0/2                         |
| 2-Hydroxypropyl methacrylate            | –                          | 1.22             | 1/3                         |
| Glycerol                                | –                          | 1.15             | 0/3                         |
| Isopropanol a                           | –                          | 1.49             | 0/5                         |
| Methyl salicylate a                     | –                          | 1.24             | 0/3                         |
| Salicylic acid a                        | +                          | 2.19             | 2/2                         |
| Sulfanilamide                           | –                          | 1.07             | 0/2                         |
| Propylene glycol                        | –                          | 1.29             | 0/2                         |

Concentrations tested for each substance are shown in Table 1. The relative fluorescence intensity of CD69 (CD69 RFI) ≥ 1.5 was the criterion to identify the response as positive. +, positive response; –, negative response. For chemicals that were predicted as positive, the maximum CD69 RFI was the maximum CD69 RFI value among all concentrations tested and among all runs tested for the chemical. For chemicals predicted as negative, the maximum CD69 RFI value was the maximum CD69 RFI value among the runs with negative prediction. a Chemicals of the 22 ICCVAM LLNA performance standards reference substances (ICCVAM, 2010).
3.2 Prediction standard
The prediction standard for the test substances was defined as the following: If a positive response can be reproduced in 2 of 3 independent runs, the prediction of the chemical is considered positive. Otherwise the prediction is considered negative. Negative results are acceptable if the highest concentration tested is high enough to exhibit cell viability < 75%, or if the highest concentration tested is 1000 µg/mL in DMSO or the test chemical’s highest soluble concentration. If consistent positive or negative responses are obtained in the first two independent runs, the third run is not needed. The prediction results for each test substance are shown in Table 3.

In addition, to accept a negative result for a substance in our test, the results of the concurrent positive control must be a positive response. In this study, the concurrent positive control in each independent run was 2 µg/mL DNCB. It was tested in 25 independent runs altogether. DNCB induced a positive response (i.e., the CD69 RFI ≥ 1.5) in all 25 runs (Tab. 4). The means of all CD69 RFI values and all cell viability values of DNCB were 2.66 ±0.47 (mean ±SD) and 81.1% ±10.6% (mean ±SD), respectively. The coefficient of variation (CV) was calculated to indicate the repeatability of the assay by dividing the standard deviation by the mean. The CVs for CD69 RFI and cell viability of DNCB were 17.7% and 13.1%, respectively. These results for the positive control on the one hand demonstrate the in-house reproducibility of our test to identify skin sensitizers, and on the other hand indicate the magnitude of the response in the positive control group and its variation range. These data supply a reference for considering the appropriateness of the result of the positive control.

3.3 The highest CD69 RFI value for each substance
For chemicals that were predicted as positive in our test, the highest CD69 RFI value induced by a chemical was the highest CD69 RFI value among all concentrations tested and among all runs tested for the chemical (Tab. 3). It could indicate the magnitude of CD69 expression elicited by the substance. For chemicals predicted as negative, the highest CD69 RFI value induced by a chemical was the highest CD69 RFI value among the runs with negative prediction (Tab. 3). Based on these highest CD69 RFI values, 27 sensitizers were correctly predicted as positive and 16 non-sensitizers were correctly predicted as negative; 7 sensitizers were falsely predicted as negative and 2 non-sensitizers were falsely predicted as positive (Tab. 3).

Among the highest RFI values for the 27 sensitizers judged as positive, the highest (17.29) was induced by the weak sensitizer hydroxycitronellal (Tab. 3). Thus, the magnitude of CD69 expression induced by the sensitizers did not appear to correlate with their skin sensitization potency classification shown in Table 1.

3.4 The sensitivity, specificity and accuracy of our test to discriminate skin sensitizers from non-sensitizers
The chemicals tested were identified as positive or negative based on the positive criteria and the prediction standard for CD69 expression described above.

Of the 34 sensitizers tested, 27 sensitizers were correctly identified as positive, 7 sensitizers were falsely identified as negative (Tab. 3). Thus, the sensitivity of the test was 79.4% (27/34). Of the 7 false negatives, oxazolone and 5-chloro-2-methyl-4-isothiazolin-3-one are extreme sensitizers; isoeugenol (prehapten) and cinnamic aldehyde (prehapten) are moderate sensitizers; cinnamal alcohol (prohapten), citral, and methyl methacrylate are weak sensitizers.

Of the 18 non-sensitizers, 16 non-sensitizers were correctly identified as negative, 2 non-sensitizers were falsely identified as positive. Thus, the specificity of the test was 88.9% (16/18) (Tab. 3). The two chemicals that were false-positive were sodium lauryl sulfate and salicylic acid (Tab. 3).

As stated above, a total of 52 substances including 34 sensitizers and 18 non-sensitizers were tested in this study, of which 27 sensitizers were correctly identified as positive and 16 non-sensitizers
Tab. 5: Comparison of the prediction results of our study with those of the OECD assays for the 52 substances

| Substances                        | Our test | DPRA | KeratinoSens™ | h-CLAT | U-SENS™ | IL-8 Luc |
|-----------------------------------|----------|------|---------------|--------|---------|---------|
| **34 sensitizers**                |          |      |               |        |         |         |
| Oxazolone                         | –        | +    | +             | +      | +       | +       |
| 5-Chloro-2-methyl-4-isothiazolin-3-one | –        | +    | +             | +      | +       | NA      |
| p-Benzoylquinone                  | +        | +    | +             | +      | +       | +       |
| 2,4-Dinitrochlorobenzene          | +        | +    | +             | +      | +       | +       |
| 4-Nitrobenzyl bromide             | +        | +    | +             | +      | +       | +       |
| Benzo[a]pyrene                    | +        | +    | +             | +      | +       | NA      |
| Glutaraldehyde                    | +        | +    | +             | +      | +       | +       |
| 4-Phenylenediamine                | +        | +    | +             | +      | +       | +       |
| Formaldehyde                      | +        | +    | +             | +      | +       | +       |
| Cobalt chloride                   | +        | +    | +             | +      | NA      | +       |
| 4-Methylaminophenol sulfate       | +        | +    | +             | +      | +       | NA      |
| Tetramethylthiuram disulfide      | +        | +    | +             | +      | +       | +       |
| 2-Methoxy-4-methylphenol          | +        | –    | –             | +      | +       | +       |
| Glyoxal                           | +        | +    | +             | +      | +       | +       |
| trans-Cinnamaldehyde              | +        | NA   | NA            | NA     | NA      | NA      |
| Isoeugenol                        | –        | +    | +             | –      | +       | +       |
| 2-Mercaptobenzothiazole           | +        | +    | +             | +      | +       | +       |
| Cinnamic aldehyde                 | –        | +    | +             | +      | +       | +       |
| m-Aminophenol                     | +        | –    | –             | +      | +       | +       |
| Diethyl maleate                   | +        | +    | +             | +      | +       | –       |
| Nickel sulfate                    | +        | +    | +             | +      | +       | +       |
| Resorcinol                        | +        | –    | –             | +      | +       | +       |
| Nickel chloride                   | +        | –    | +             | +      | NA      | +       |
| Citral                            | –        | +    | +             | +      | +       | +       |
| Hexyl cinnamaldehyde              | +        | –    | +             | –      | +       | +       |
| Eugenol                           | +        | +    | –             | +      | +       | +       |
| Phenyl benzoate                   | +        | +    | –             | +      | +       | +       |
| Cinnamic alcohol                  | –        | +    | +             | +      | +       | +       |
| Cyclamen aldehyde                 | +        | +    | NA            | –      | +       | +       |
| Hydroxycitronellal                | +        | +    | +             | +      | +       | +       |
| Imidazolidinyl urea               | +        | +    | +             | +      | +       | +       |
| Linalool                          | +        | –    | –             | +      | +       | +       |
| Ethyl acrylate                    | +        | +    | +             | –      | +       | NA      |
| Methyl methacrylate               | –        | +    | +             | +      | +       | –       |
| **18 non-sensitizers**            |          |      |               |        |         |         |
| Sodium lauryl sulfate             | +        | –    | –             | –      | +       | +       |
Substances | Our test | DPRA | KeratinoSens™ | h-CLAT | U-SENS™ | IL-8 Luc
---|---|---|---|---|---|---
Ethylene glycol dimethacrylate | − | + | + | + | + | −
Xylene | − | − | − | − | + | −
Propyl paraben | − | − | + | + | + | −
Caprylic (octanoic) acid | − | − | − | + | + | −
Benzalkonium chloride | − | − | − | − | + | +
Chlorobenzene | − | − | − | + | − | −
4-Aminobenzoic acid | − | − | − | − | − | −
Lactic acid | − | − | − | − | − | −
Diethyl phthalate | − | − | − | + | + | +
Dimethyl isophthalate | − | NA | + | NA | NA | −
2-Hydroxypropyl methacrylate | − | + | NA | − | NA | −
Glycerol | − | − | − | − | − | −
Isopropanol | − | − | − | − | − | −
Methyl salicylate | − | − | − | − | − | −
Salicylic acid | + | + | − | + | − | −
Sulfanilamide | − | − | − | − | − | −
Propylene glycol | − | − | − | − | − | −

Sensitivity a 79.4% (27/34) 81.8% (27/33) 81.2% (26/32) 87.9% (29/33) 100%* (31/31) 93.1% (27/29)
Specificity a 88.9% (16/18) 82.4% (14/17) 82.4% (14/17) 58.8% (10/17) 62.5% (10/16) 83.3% (15/18)
Accuracy a 82.7% (43/52) 82% (41/50) 81.6% (40/49) 78% (39/50) 87.2% (41/47) 89.4% (42/47)
Sensitivity b 78.8% (26/33) 82.4% (14/17)
Specificity b 88.2% (15/17)
Accuracy b 82% (41/50) 82% (41/50)
Sensitivity c 78.1% (25/32) 81.2% (26/32)
Specificity c 88.2% (15/17) 82.4% (14/17)
Accuracy c 81.6% (40/49) 81.6% (40/49)
Sensitivity d 78.8% (26/33) 87.9% (29/33)
Specificity d 88.2% (15/17) 58.8% (10/17)
Accuracy d 82% (41/50) 78% (39/50)
Sensitivity e 77.4% (24/31) 100%* (31/31)
Specificity e 87.5% (14/16) 62.5% (10/16)
Accuracy e 80.8% (38/47) 87.2% (41/47)
Sensitivity f 79.3% (23/29) 93.1% (27/29)
Specificity f 88.9% (16/18) 83.3% (15/18)
Accuracy f 83.0% (39/47) 89.4% (42/47)

+, positive response; −, negative response; NA, not available; *, p<0.05. Chi-square test was used to compare the differences of the sensitivity, specificity and accuracy of this test model with that of the DPRA, the KeratinoSens, the h-CLAT, the U-SENS, and the IL-8 Luc based on the chemicals with available data in each assay or based on only chemicals with available data in the DPRA, KeratinoSens, h-CLAT, U-SENS, or IL-8 Luc. Software of Statistical Product and Service Solutions 17.0 (SPSS 17.0) was used for the comparisons.
were correctly identified as negative (Tab. 3). Thus, the accuracy of our test based on the 52 substances was 82.7% ((27+16)/52).

All 22 substances of the LLNA performance standards reference substances (ICCVAM, 2010) were tested in this study. They included 14 sensitizers and 8 non-sensitizers (Tab. 3). Nine out of the 14 sensitizers were correctly identified as positive, and 6 out of the 8 non-sensitizers were correctly identified as negative (Tab. 3). Thus, the sensitivity, specificity and accuracy of our test based on only these 22 substances was 64.3% (9/14), 75% (6/8), and 68.2 ((9+6)/22), respectively. These values were lower than the overall sensitivity (79.4%), specificity (88.9%) and accuracy (82.7%) based on the 52 substances.

### 3.5 Comparison of the sensitivity, specificity and accuracy of our test to identify skin sensitizers with the DPRA, the KeratinoSens™, the h-CLAT, the U-SENS™ and the IL-8 Luc

The direct peptide reactivity assay (DPRA) (OECD, 2015a), the in vitro skin sensitisation: ARE-Nrf2 luciferase test method (KeratinoSens™) (OECD, 2015b), the human cell line activa-

| Substances                          | Correlation of CD69 RFI with concentrations tested | Correlation of cell viability with concentrations tested |
|-------------------------------------|----------------------------------------------------|--------------------------------------------------------|
|                                     | R        | p          | R        | p          |
| p-Benzoquinone                     | 0.975    | 0.002      | -0.950   | 0.007      |
| 2,4-Dinitrochlorobenzene           | 0.951    | 0.024      | -0.900   | 0.05       |
| 4-Nitrobenzyl bromide              | 0.879    | 0.01       | -0.428   | 0.199      |
| Glutaraldehyde                     | 0.948    | 0.026      | -0.931   | 0.034      |
| 4-Phenylenediamine                 | 0.774    | 0.062      | -0.719   | 0.085      |
| Formaldehyde                       | 0.891    | 0.009      | -0.782   | 0.033      |
| Cobalt chloride                    | 0.250    | 0.316      | -0.973   | 0.001      |
| 4-Methylaminophenol sulfate        | 0.992    | 0.004      | -0.868   | 0.066      |
| Benzo[a]pyrene                     | 0.845    | 0.004      | -0.641   | 0.043      |
| Tetramethylthiuram disulfide       | 0.990    | 0.001      | -0.913   | 0.015      |
| 2-Methoxy-4-methylphenol           | 0.793    | 0.055      | -0.850   | 0.034      |
| Glyoxal                            | 0.938    | 0.003      | -0.961   | 0.001      |
| trans-Cinnamaldehyde               | 0.994    | 0.000      | -0.961   | 0.005      |
| 2-Mercaptobenzothiazole            | 0.908    | 0.002      | -0.882   | 0.004      |
| m-Aminophenol                      | 0.517    | 0.186      | -0.938   | 0.009      |
| Diethyl maleate                    | 0.967    | 0.004      | -0.990   | 0.001      |
| Nickel sulfate                     | 0.717    | 0.141      | -0.970   | 0.015      |
| Resorcinol                         | 0.044    | 0.467      | -0.783   | 0.033      |
| Nickel chloride                    | 0.834    | 0.04       | -0.990   | 0.001      |
| Hexyl cinnamaldehyde               | 0.960    | 0.02       | -0.989   | 0.005      |
| Eugenol                            | 0.564    | 0.218      | -0.986   | 0.007      |
| Phenyl benzoate                    | 0.605    | 0.198      | 0.321    | 0.339      |
| Cyclamen aldehyde                  | 0.996    | 0.002      | -0.942   | 0.029      |
| Hydroxycitronellal                 | 0.940    | 0.000      | -0.899   | 0.000      |
| Imidazolidinyl urea                | 0.949    | 0.026      | -0.958   | 0.021      |
| Linalool                           | 0.983    | 0.008      | -0.108   | 0.446      |
| Ethyl acrylate                     | 0.945    | 0.028      | -0.987   | 0.006      |

Pearson linear correlation analysis was conducted to analyze the magnitude of the linear correlation of the dose-effect relationship shown in Figure 1; R, Pearson linear correlation coefficient; p, statistical significance for the linear correlation; Software of Statistical Product and Service Solutions 17.0 (SPSS 17.0) was used for the analysis.
Fig. 1: Dose-effect relationship of CD69 RFI (open circles “○”) and cell viability (filled circles “●”) for the 27 skin sensitizers showing a positive response

(1) p-benzoquinone;
(2) 2,4-dinitrochlorobenzene;
(3) 4-nitrobenzyl bromide;
(4) glutaraldehyde;
(5) 4-phenylenediamine;
(6) formaldehyde;
(7) cobalt chloride;
(8) 4-methylaminophenol sulfate;
(9) tetramethylthiuram disulfide;
(10) 2-methoxy-4-methylphenol;
(11) glyoxal;
(12) trans-cinnamaldehyde;
(13) 2-mercaptobenzothiazole;
(14) benzylalcohol;
(15) m-aminophenol;
(16) diethyl maleate;
(17) nickel sulfate;
(18) resorcinol;
(19) nickel chloride;
(20) hexyl cinnamic aldehyde;
(21) eugenol;
(22) phenyl benzoate;
(23) cyclamen aldehyde;
(24) hydroxycitronellal;
(25) imidazolidinyl urea;
(26) linalool;
(27) ethyl acrylate.
tion test (h-CLAT) (OECD, 2018); the U937 cell line activation test (U-SENS™) (OECD, 2018), and the interleukin-8 reporter gene assay (IL-8 Luc) (OECD, 2018) are the *in vitro* assays for skin sensitization that have been formally adopted by the OECD. They model the first three of the four KEs, while the assay described here models the fourth AOP KE for skin sensitization. The sensitivity, specificity and accuracy of this assay was compared with that of the DPRA, the KeratinoSens™, the h-CLAT, the U-SENS™ and the IL-8 Luc, respectively, to assess the comparative performance of our test.

For the comparison, the reported data on the prediction results of the 52 chemicals in the DPRA (Nukada et al., 2013; Urbisch et al., 2016; Hoffmann et al., 2018; Cho et al., 2020), KeratinoSens (Emter, 2010; Urbisch et al., 2016; Hoffmann et al., 2018; Cho et al., 2020), the h-CLAT (Nukada et al., 2012, 2013; Hoffmann et al., 2018; Cho et al., 2020), the h-CLAT (Nukada et al., 2012, 2013; Hoffmann et al., 2018; Cho et al., 2020), the U-SENS (Piroird et al., 2015; Hoffmann et al., 2018), and the h-CLAT (Takahashi et al., 2011; Kimura et al., 2015) were used (Tab. 5). The sensitivity, specificity and accuracy of our test, the DPRA, the KeratinoSens, the h-CLAT, the U-SENS, and the IL-8 Luc were calculated based on the chemicals with available data in each assay (Tab. 5). Next, the sensitivity, specificity and accuracy of our test were calculated based on only the chemicals with available data in the DPRA (33 sensitizers and 17 non-sensitizers). Also, the sensitivity, specificity and accuracy of our test were calculated based on only the chemicals with available data in the KeratinoSens (32 sensitizers and 17 non-sensitizers). Then, the sensitivity, specificity and accuracy of our test were calculated based on only chemicals with available data in the h-CLAT (33 sensitizers and 17 non-sensitizers). Further, the sensitivity, specificity and accuracy of our test were calculated based on only chemicals with available data in the U-SENS (31 sensitizers and 16 non-sensitizers). Finally, the sensitivity, specificity and accuracy of our test were calculated based on only the chemicals with available data in the IL-8 Luc (29 sensitizers and 18 non-sensitizers). The chi-square test was used for the comparisons.

There were no statistically significant differences for any of the comparisons except for the difference in sensitivity between our assay and the U-SENS™ (*p < 0.05*) (Tab. 5). Although not statistically significant, our test showed a slightly lower sensitivity and a higher specificity than the 5 OECD assays (Tab. 5).

### 3.6 The dose-effect relationship of CD69 expression and cell viability

For the 27 sensitizers showing a positive response in our test, the dose-effect relationships of CD69 expression and cell viability are shown in Figure 1. The panels show that an increase in CD69 RFI with increasing concentrations of test chemical was associated with a decrease in cell viability. Pearson linear correlation coefficient (R) values with *p*-values show the magnitude of the linear correlation (Tab. 6).

Of the 27 R-values for the relationship between CD69 RFI and the concentrations tested, 15 R-values were greater than 0.9, 19 were greater than 0.8, and only 2 were smaller than 0.5 (Tab. 6). Of the 27 *p*-values, 13 *p*-values were smaller than 0.01 and 19 were smaller than 0.05 (Tab. 6). Thus, for most sensitizers, the increase in CD69 expression had a statistically significant correlation with the concentrations tested.

Of the 27 R-values for the relationship between cell viability and the concentrations tested, 16 R-values were greater than 0.9, 20 were greater than 0.8, and only 3 were smaller than 0.5 (Tab. 6). Of the 27 *p*-values, 12 were smaller than 0.01 and 22 were smaller than 0.05 (Tab. 6). Thus, for most sensitizers, the decrease in cell viability had statistically significant correlation with the concentrations tested.

### 3.7 The EC1.5 value

For the 27 sensitizers showing a positive result, the EC1.5 values, i.e., the concentration at which a test chemical induced a CD69 RFI of 1.5, were calculated according to the following equation to assess their skin sensitizing potency. The equation is based on the same rule as for the calculation of LLNA EC3.

\[
EC1.5 = B_{\text{conc.}} + [(1.5 - A_{RFI})/(A_{RFI} - B_{RFI})] \times (A_{\text{conc.}} - B_{\text{conc.}}),
\]

where \(A_{\text{conc.}}\) is the lowest concentration in µg/mL with CD69 RFI ≥ 1.5; \(B_{\text{conc.}}\) is the highest concentration in µg/mL with CD69 RFI < 1.5; \(A_{RFI}\) is the CD69 RFI at the lowest concentration with CD69 RFI ≥ 1.5; \(B_{RFI}\) is the CD69 RFI at the highest concentration with CD69 RFI < 1.5.

The EC1.5 values are shown in Table 7. For the potency classification, the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) used 1% of the LLNA EC3 as the threshold to separate strong sensitizers (extreme and strong in LLNA) from weak sensitizers (moderate and weak in LLNA) (ECETOC, 2003; Loveless et al., 2010). The threshold to separate strong sensitizers (extreme and strong in LLNA) from weak sensitizers (moderate and weak in LLNA) in the h-CLAT was 10µg/mL (Nukada et al., 2012). EC1.5 values in our test were significantly correlated with the minimum induction threshold (MIT) in the h-CLAT (*R = 0.588, P = 0.01*) (Tab. 7). When 10 µg/mL was also used in our test as the threshold for the classification, the predictivity for the strong sensitizers (extreme and strong in LLNA) was 7/9 = 77.8%, the predictivity for the weak sensitizers (moderate and weak in LLNA) was 16/18 = 88.9%, and the total predictivity was (7+16)/(9+18) = 85.2%. Thus 10µg/mL may also be an appropriate threshold for our test to separate the strong sensitizers (extreme and strong in LLNA) from the weak sensitizers (moderate and weak in LLNA).

### 4 Discussion

In this study, a novel *in vitro* test for skin sensitization based on T cell activation was investigated. The Jurkat Clone E6-1 human T cells were incubated directly with the test substances and CD69 expression on the T cells was determined by flow cytometry to show early T cell activation induced by sensitizers. No APCs were involved in this model, which made the procedures much simpler than for the other reported assays (Richter et al., 2013; Vocanson et al., 2014). Although no APCs were involved in the...
model, CD69 expression on the T cells indeed was induced by most of the sensitizers.

It is not the main purpose of this study to determine the mechanisms underlying our test, but we hypothesize the following: (1) During incubation, the sensitizers may bind proteins in the fetal bovine serum contained in the culture medium to form a protein-hapten (chemical) complex containing chemical (hapten) specific epitopes. The epitopes may be the same as those presented in vivo by APCs. (2) The protein-hapten (chemical) complexes may bind the T cell antigen receptors (TCRs) on the Jurkat T cells directly in this in vitro condition without the aid of APCs. (3) Like a naïve T cell, the Jurkat Clone E6-1 human T cell line expresses CD3 and TCRs and is commonly used in in vitro studies on human T cell activation (Fernández-Riejos et al., 2008; Pan et al., 2015; Ngo et al., 2017; Chen et al., 2018; Vis et al., 2018; Colin-York et al., 2019; Kim et al., 2019). (4) It ap-

| Tab. 7: Comparison of EC1.5 values of the 27 sensitizers showing a positive response in our study with the EC3 values in LLNA and the MIT values in the h-CLAT |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Substances      | LLNA potency    | EC3 in LLNA (%) | MIT in h-CLAT   | EC1.5 in our study |
|                 | category        |                  | (μg/mL)         | (μg/mL) (%)       |
| p-Benzquinone   | extreme         | 0.0099<sup>a</sup> | 2.25<sup>a</sup> | 2.36 / 0.000236  |
| 2,4-Dinitrochlorobenzene | extreme | 0.05<sup>a</sup> | 2.3<sup>a</sup> | 0.94 / 0.000094  |
| 4-Nitrobenzyl bromide | extreme | 0.05<sup>a</sup> | 0.91<sup>a</sup> | 0.17 / 0.000017  |
| Benz[a]pyrene   | extreme         | 0.0009<sup>b</sup> | NA              | 19.2 / 0.00192   |
| Glutaldehyde    | strong          | 0.1<sup>a</sup>  | 2.7<sup>a</sup> | 2.17 / 0.000217  |
| 4-Phenylenediamine | strong  | 0.16<sup>a</sup> | 2.09<sup>a</sup> | 2.48 / 0.000248  |
| Formaldehyde    | strong          | 0.61<sup>a</sup> | 4.3<sup>a</sup> | 4.11 / 0.000411  |
| Cobalt chloride | strong          | 0.38<sup>a</sup> | 35.5<sup>a</sup> | 40.2 / 0.00402   |
| 4-Methylaminophenol sulfate | strong | 0.8<sup>c</sup>  | 12.7<sup>a</sup> | 2.78 / 0.000278  |
| Tetramethylthiuram disulfide | moderate | 5.2<sup>a</sup>  | 2.46<sup>a</sup> | 3.22 / 0.000322  |
| 2-Methoxy-4-methylphenol | moderate | 5.8<sup>a</sup>  | 30.8<sup>a</sup> | 54.2 / 0.00542   |
| Glyoxal         | moderate        | 1.4<sup>a</sup>  | 286.7<sup>a</sup> | 46.3 / 0.00463   |
| trans-Cinnamaldehyde | moderate | 1.4<sup>c</sup>  | NA              | 4 / 0.0004      |
| 2-Mercaptobenzothiazole | moderate | 1.7<sup>a</sup>  | 57.5<sup>a</sup> | 69.2 / 0.00692   |
| m-Aminophenol   | moderate        | 3.3<sup>a</sup>  | 117.1<sup>a</sup> | 39.3 / 0.00393   |
| Diethyl maleate | moderate        | 5.8<sup>a</sup>  | 64<sup>a</sup>    | 35.7 / 0.00357   |
| Nickel sulfate  | moderate        | 4.8<sup>a</sup>  | 42.2<sup>a</sup> | 105.8 / 0.01058  |
| Resorcinol      | moderate        | 5.7<sup>a</sup>  | 200.9<sup>a</sup> | 207.9 / 0.02079  |
| Nickel chloride | moderate        | 3.5<sup>d</sup>  | NA              | 56.2 / 0.00562   |
| Hexyl cinnamic aldehyde | weak | 11<sup>a</sup> | negative<sup>a</sup> | 12.7 / 0.00127   |
| Eugenol         | weak            | 13<sup>a</sup>  | 64.4<sup>a</sup> | 49.5 / 0.00495   |
| Phenyl benzoate | weak            | 20<sup>a</sup>  | 166.2<sup>a</sup> | 61.2 / 0.00612   |
| Cyclamen aldehyde | weak         | 22<sup>a</sup>  | negative<sup>a</sup> | 32.1 / 0.00321   |
| Hydroxycitronellal | weak          | 33<sup>a</sup>  | 26.8<sup>a</sup> | 20.0 / 0.002     |
| Imidazolidinyl urea | weak          | 24<sup>a</sup>  | 39.3<sup>a</sup> | 90.7 / 0.00907   |
| Linalool        | weak            | 30<sup>a</sup>  | 68.3<sup>a</sup> | 408.1 / 0.04081  |
| Ethyl acrylate  | weak            | 32.8<sup>c</sup> | negative<sup>a</sup> | 265.4 / 0.02654  |

LLNA, murine local lymph node assay; h-CLAT, human cell line activation test; EC3 in LLNA, the concentration needed to produce an SI of 3 in the LLNA; MIT, minimal induction threshold in the h-CLAT; EC1.5 in our study, the concentration at which a test chemical induced a CD69 RFI of 1.5; NA, not available; <sup>a</sup> data from Nukada et al. (2012); <sup>b</sup> data from Urbisch et al. (2016); <sup>c</sup> data from ICCVAM (2010); <sup>d</sup> data from Basketter et al. (2012); <sup>e</sup> data from Hoffmann et al. (2018).
pears that CD69 expression on the surface of T cells is trigged by TCR activation (Testi et al., 1989; Ziegler et al., 1994; Cimo et al., 2013). Thus, upon binding of the protein-hapten (chemical) complexes to the TCRs on the Jurkat cell, the TCRs are activated (i.e., the first signal for T cell activation), inducing CD69 expression. The second signal for T cell activation, i.e., co-stimulation of APC-expressed CD80/CD86 and CD28 on T cells does not contribute to CD69 expression in this test model, because there are no APCs in the test system. This hypothesis of the molecular mechanisms will need to be investigated in further studies.

No matter what the molecular mechanisms mediating CD69 expression on the T cells by the sensitizers in this test model are, we think that this test may be able to predict skin sensitizers based on the following aspects: (1) Most of the sensitizers selected were reference substances used previously for challenging in vitro assays for skin sensitization (Sens-it-iv, 2009; Chipinda et al., 2011; Hennen et al., 2011; Emter et al., 2010; Nukada et al., 2012; Natsch et al., 2013). (2) Compared to the vehicle control, most sensitizers tested induced an increase in CD69 expression in the Jurkat Clone E6-1 T lymphocytes. For most sensitizers inducing a positive response, the increases showed a statistically significant linear correlation with the tested concentrations. The statistically significant linear dose-effect relationships could indicate causal links between sensitizers and CD69 expression, supporting the relevance of the test. (3) The concurrent positive control, i.e., 2 µg/mL DNCB, was reproduced in all of the 25 independent runs conducted (Tab. 4), indicating in-house reproducibility of this test model. (4) The accuracy of our test based on the 52 reference chemicals was not statistically significantly different from that of the DPRA, the KeratinoSens™, the h-CLAT, the U-SENS™ or the IL-8 Luc (Tab. 5). (5) The EC1.5 values obtained in this test model may contribute to the assessment of sensitization potency of chemicals in the context of the IATA for skin sensitization.

The predictivity of other T cell-based assays for skin sensitization has been tested based only on a limited number of substances, which mainly were extreme sensitizers (Dietz et al., 2010; Richter et al., 2013; Vocanson et al., 2014; Coulter et al., 2008; Gibson et al., 2015; Ahmed et al., 2016). In contrast, the predictivity of our T cell-based test was assessed based on 52 substances including extreme, strong, moderate and weak sensitizers. Eight of the 11 weak sensitizers were correctly identified as sensitizers. Thus, this test model may have a broad ability to identify sensitizers. The results showed that this test model had a somewhat lower sensitivity and a higher specificity to test sensitizers (Tab. 5).

The magnitude of CD69 expression generally did not correlate with the potency of the sensitizers. For example, the extreme sensitizers oxazolone and 5-chloro-2-methyl-4-isothiazolin-3-one showed negative results. In contrast, the highest CD69 RFI value (17.29) was induced by the weak sensitizer hydroxycitro-nellal (Tab. 3). The mechanisms, which may relate to the TCR repertoire diversity (Esser et al., 2014), are not clear. Possibly, the more epitopes of the chemical that are recognized by TCRs on the T cells, the better the CD69 expression will be induced by the chemical (Esser et al., 2014). Although CD69 expression generally did not correlate with the potency of the sensitzers, the results indicated that the EC1.5 value for each chemical may be used to classify its skin sensitization potency.

Some false predictions occurred in this study, which included 7 sensitizers and 2 non-sensitizers. Of the 7 false-negative sensitizers, oxazolone and 5-chloro-2-methyl-4-isothiazolin-3-one are extreme sensitizers, isoeugenol (prehapten) and cinnamaldehyde (prehapten) are moderate sensitizers, and cinnamic alcohol (prohapten), citral and methyl methacrylate are weak sensitizers. Sodium lauryl sulfate and salicylic acid were the two false-positives. Except for oxazolone and cinnamaldehyde, the other 7 falsely predicted chemicals were among the 22 substances of the LLNA performance standards reference substances (ICCVAM, 2010), which reduced the accuracy of our test based only on those 22 substances (63.6%) compared to its overall accuracy (82.7%) based on all 52 substances.

The false predictions occurring in our test show its limitations. We consider that the causes for the false predictions may include the following:

Firstly, the TCR repertoire may be limited in our test as the Jurkat cell line represents only a single “donor”. This hypothesis could be investigated by using other T cell lines from different donors, e.g., five donors as required in the human T cell priming assay (hTCPA) (Richter et al., 2013).

Secondly, our test does not encompass a metabolic system. As a result, pre- and prohapten may not be metabolized to reactive derivatives, which may affect their binding to nucleophilic sites in proteins to form hapten-protein complexes. However, although the pre/prohapten isoeugenol, cinnamaldehyde and cinnamic alcohol were false-negative in this study, the other pre/prohapten 2-methoxy-4-methylphenol, benzo[a]pyrene, 4-phenylenediamine, resorcinol, 4-methylyaminophenol sulfate, m-aminophenol, eugenol, and fimalool showed positive results. Thus, a lack of metabolic capacity does not seem to be a main cause of false-negative results. Also, the OECD-adopted in vitro assays also have limited metabolic capacity, but most pre/prohapten are correctly identified by the assays (Nukada et al., 2012, 2013; Emter et al., 2010; Piroir et al., 2015; Takahashi et al., 2011; Kimura et al., 2015, 2018; Patlewicz et al., 2016). However, improving the metabolic capacity by adding rat liver S9 fractions to the KeratinoSens assay or by coculture of HaCaT keratinocytes with THP-1 in the h-CLAT increased the response to some pre/prohapten tested (Hennen et al., 2011; Cao et al., 2012; Natsch and Haupt, 2013). Thus, for sensitizers with negative results, improving the metabolic capacity of our test may be considered.

Thirdly, the relevance of our test to represent the complex KE4 of the AOP for skin sensitization may be limited, especially as it does not include APCs. Others already have stated that in vitro assays to assess T cell activation would inevitably have differences compared to the in vivo conditions (Richter et al., 2013; Vocanson et al., 2014). In spite of this limitation, our test may contribute to the development of an in vitro assay to assess T cell activation based on its good performance in testing 52 chemicals. The molecular mechanisms and related in vivo relevance of our test needs be further clarified.
Fourthly, the fetal bovine serum used in the test may bind and present the test chemicals differently than human proteins would. Therefore, it could be replaced with human serum in the cell culture medium (Belot et al., 2017) to achieve a fully human model.

Apart from possible technical benefits, replacing fetal bovine serum, bovine serum albumin and animal-derived antibodies with tools that are not derived from animals has benefits for animal welfare. The bovine serum albumin used for blocking in this assay may be replaced by human serum albumin; and the mouse anti-human anti-CD69 antibody used in this assay may be replaced by an antibody from a non-animal source (Edwards et al., 2018). Adapting cells to serum-free culture medium (e.g., HL-1™ and X-VIVO™10) for cell culture and cryopreservation (Marigliani et al., 2019) may be feasible solutions; however, proteins are essential for the formation of the protein-hapten complex and will need to be included in the test conditions. On the other hand, serum proteins may not be ideal for this purpose, because they contain only 10% lysine and very few cysteine residues (OECD, 2012). Moreover, target sites (e.g., cysteine or lysine) located on an exposed surface of a protein are more likely to react with an electrophile than ones located within a groove or fold of a protein. Such steric constraints are imposed by the primary structure (i.e., amino acid sequence) of the peptide or protein, as well as the secondary and tertiary structure of proteins (OECD, 2012). Trying to refine the protein components in the culture medium may improve the prediction of the false negatives in this study.

For the two false positives, sodium lauryl sulfate and salicylic acid, it is difficult to explain why they tested positive in this study. Sodium lauryl sulfate is a surfactant and belongs to the SN2 (substitution nucleophilic bi-molecular) Toxtree protein binding class (Piroird et al., 2015); salicylic acid is a preservative. Both are moderate skin irritants. It could be supposed that their irritant properties disrupted the cell membrane of the Jurkat T cells, which may induce CD69 expression on the cell membrane. In addition, sodium lauryl sulfate showed positive results in the LLNA, the U-SENS™, the IL-8 Luc (Tab. 5) and other in vitro skin sensitization studies (Herouet et al., 1999; Cumberbatch et al., 2002; Lim et al., 2008; Lee et al., 2020). Salicylic acid showed positive results in the U-SENS™ and the h-CLAT (Tab. 5). It was reported that salicylic acid induced an increase in CD54 expression in THP-1 cells by activation of NLRP3 inflammasomes (Mitachi et al., 2019). Considering that these positive results for sodium lauryl sulfate and salicylic acid appear to relate to different key events of skin sensitization, the relevance of the false-positive results in our study is unclear.

Based on the results of our study and what is discussed above, much work needs to be done to clarify the molecular mechanisms of the test to prove its relevance in modeling KE 4 and to refine the assay to further improve its predictivity.

In conclusion, the performance of a novel in vitro skin sensitization assay based on T lymphocyte activation was tested with 52 reference chemicals. The results indicate that the test may be useful to predict skin sensitizers. This work could contribute to the development of an in vitro assay for skin sensitization based on activation of T cells.

References
Ahmed, S. S., Wang, X. N., Fielding, M. et al. (2016). An in vitro human skin test for assessing sensitization potential. J Appl Toxicol 36, 669-684. doi:10.1002/jat.3197
Ashby, J., Hilton, J., Dearman, R. J. et al. (1993). Mechanistic relationship among mutagenicity, skin sensitization, and skin carcinogenicity. Environ Health Perspect 101, 62-67. doi:10.1289/ehp.931062
Avgustin, B., Kotnik, V., Skoberne, M. et al. (2005). CD69 expression on CD4+ T lymphocytes after in vitro stimulation with tuberculin is an indicator of immune sensitization against Mycobacterium tuberculosis antigens. Clin Diagn Lab Immunol 12, 101-106. doi:10.1128/CDLI.12.1.101-106.2005
Basketter, D., Kolle, S. N., Schrage, A. et al. (2012). Experience with local lymph node assay performance standards using standard radioactive and nonradioactive cell count measurements. J Appl Toxicol 32, 590-596 doi:10.1002/jat.1684
Bavandi, A., Fahrngruber, H., Aschauer, H. et al. (2006). Pimecrolimus and tacrolimus differ in their inhibition of lymphocyte activation during the sensitization phase of contact hypersensitivity. J Dermatol Sci 43, 117-126. doi:10.1016/j.jdermsci.2006.04.001
Beeler, A., Zaccaria, L., Kawabata, T. et al. (2008). CD69 upregulation on T cells as an in vitro marker for delayed-type drug hypersensitivity. Allergy 63, 181-188. doi:10.1111/j.1398-9995.2007.01516.x
Belot, N., Bushra, S., Christopher, L. et al. (2017). Adaptation of the KeratinoSens™ skin sensitization test to animal-product-free cell culture. ALTEX 34, 560-564. doi:10.14573/altex.1701311
Cao, Y. P., Ma, P. C., Liu, W. D. et al. (2012). Evaluation of the skin sensitization potential of chemicals in THP-1/keratinocyte co-cultures. Immunopharmacol Immunotoxicol 34, 196-204. doi:10.3109/08923973.2011.591800
Casey, W. M. (2016). Advances in the development and validation of test methods in the United States. Toxicol Res 32, 9-14. doi:10.5487/TR.2016.32.1.009
Chakraborty, A. K. and Weiss, A. (2014). Insights into the initiation of TCR signaling. Nat Immunol 15, 798-807. doi:10.1038/ni.2940
Chen, J., Li, Q., Pang, Z. et al. (2018). Titanium ions promote exogenous calcium-dependent calcium influx in activated Jurkat T cells: A possible mechanism to explain its immunostimulatory properties. Mediators Inflamm 2018, 560-564. doi:10.14573/altex.1701311
Chipinda, I., Ruwona, T. B., Templeton, S. P. et al. (2011). Use of the human monocytic leukemia THP-1 cell line and co-incubation with microsomes to identify and differentiate hapten and prohapten sensitizers. Toxicology 280, 196-204. doi:10.1016/j.tox.2010.12.004
Cho, S. A., Choi, M., Park, S. R. et al. (2020). Application of Spectro-DPRA, KeratinoSens™ and h-CLAT to estimation of the skin sensitization potential of cosmetics ingredients. J Appl Toxicol 40, 300-312. doi:10.1002/jat.3904
Cimo, A. M., Ahmed, Z., McIntyre, B. W. et al. (2013). CD25 and CD69 induction by α4β1 outside-in signalling requires...
TCR early signalling complex proteins. Biochem J 454, 109-121. doi:10.1042/BJ20130485

Colin-York, H., Kumari, S., Barbieri, L. et al. (2019). Distinct actin cytoskeleton behaviour in primary and immortalised T-cells. J Cell Sci 133, jcs232322. doi:10.1242/jcs.232322

Corsini, E., Papale, A., Galbiati, V. et al. (2014). Safety evaluation of cosmetic ingredients: In vitro opportunities for the identification of contact allergens. Cosmetics 1, 61-74. doi:10.3390/cosmetics1010061

Coulter, E. M., Jenkinson, C., Wu, Y. et al. (2008). Activation of T-cells from allergic patients and volunteers by p-phenylenediamine and Bandrowski’s base. J Invest Dermatol 128, 897-905. doi:10.1038/sj.jid.5701071

Cumberbatch, M., Dearman, R. J., Groves, R. W. et al. (2002). Novel keratinocyte-based reporter cell line to screen skin sensitizers in vitro. Toxicol Appl Pharmacol 154, 61-620. doi:10.1006/taap.2002.9442

D’Ambrosio, D., Cantrell, D. A., Frati, L. et al. (1994). Involvement of p21ras activation in T cell CD69 expression. J Eur Immunol 24, 616-620. doi:10.1002/eji.107

Dietz, L., Esser, P. R., Schmucker, S. S. et al. (2010). Tracking human contact allergens: From mass spectrometric identification of peptide-bound reactive small chemicals to chemical-specific naive human T-cell priming. Toxicol Sci 117, 336-347. doi:10.1093/toxsci/kfq209

Dimiţrova, P., Alipieva, K., Grozdanova, T. et al. (2018). New irorids from Verbascum nobile and their effect on lectin-induced T cell activation and proliferation. Food Chem Toxicol 111, 605-615. doi:10.1016/j.fct.2017.11.060

ECETOC (2003). Contact Sensitisation: Classification According to Potency. Technical Report No. 87. European Centre for Ecotoxicology and Toxicology of Chemicals, Brussels, Belgium

Edwards, A., Roscoe, L., Longmore, C. et al. (2018). Adaptation of the human cell line activation test (h-CLAT) to animal-product-free conditions. ALTEX 35, 477-488. doi:10.14573/altex.1710051

Emter, R., Ellis, G. and Natsch, A. (2010). Performance of a novel keratinocyte-based reporter cell line to screen skin sensitizers in vitro. Toxicol Appl Pharmacol 15, 281-290. doi:10.1016/j.taap.2010.03.009

Esser, P. R., Kimber, I. and Martin, S. F. (2014). Correlation of contact sensitizer potency with T cell frequency and TCR repertoire diversity. Exp Suppl 104, 101-114. doi:10.1007/978-3-0348-0726-5_8

EU (2009). Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products. OJ L342, 59-209. https://eur-lex.europa.eu/eli/reg/2009/1223/oj

Ezendaran, J., Braakhuis, H. M. and Vandebriel, R. J. (2016). State of the art in non-animal approaches for skin sensitization testing: From individual test methods towards testing strategies. Arch Toxicol 90, 2861-2883. doi:10.1007/s00204-016-1842-4

Fernández-Riejos, P., Gobena, R. and Sánchez-Margalef, V. (2008). Leptin promotes stem cell survival and activates Jurkat T lymphocytes by stimulation of mitogen-activated protein kinase. Clin Exp Immunol 151, 505-518. doi:10.1111/j.1365-2249.2007.03563.x

Gibson, A., Kim, S. H., Faulkner, L. et al. (2015). In vitro priming of naïve T-cells with p-phenylenediamine and Bandrowski’s base. Chem Res Toxicol 28, 2069-2077. doi:10.1021/acs.chemrestox.5b00294

Green, K. J., Rowbottom, D. G. and Mackinnon, L. T. (2003). Acute exercise and T-lymphocyte expression of the early activation marker CD69. Med Sci Sports Exerc 35, 582-588. doi:10.1249/01.MSS.0000058361.82096.26

Hennen, J., Aeby, P., Goebel, C. et al. (2011). Cross talk between keratinocytes and dendritic cells: Impact on the prediction of sensitization. Toxicol Sci 123, 501-510. doi:10.1093/toxsci/kfr174

Hou et al. (2020). ALTEX 37(3), 2020

Hou et al.

Jaworska, J. S. (2016). Integrated testing strategies for skin sensitization hazard and potency assessment – State of the art and challenges. Cosmetics 3, 16. doi:10.3390/cosmetics3020016

Jowsey, I. R., Basketter, D. A., Westmoreland, C. et al. (2006). A future approach to measuring relative skin sensitising potency: A proposal. J Appl Toxicol 26, 341-350. doi:10.1002/jat.1146

June, C. H., Ledbetter, J. A., Linsley, P. S. et al. (1990). Role of the CD28 receptor in T-cell activation. Immunol Today 11, 211-216. doi:10.1016/0167-5699(90)90085-N

Kim, H. J., Woo, J., Nam, Y. R. et al. (2019). Flos Magnoliae and its constituent linoleic acid suppress T lymphocyte activation via store-operated calcium entry. Am J Chin Med 29, 1-15. doi:10.1124/S0192415X19500836

Kimura, Y., Fujimura, C., Ito, Y. et al. (2015). Optimization of the IL-8 Luc assay as an in vitro test for skin sensitization. Toxicol In Vitro 29, 1816-1830. doi:10.1016/j.tiv.2015.07.006

Kimura, Y., Fujimura, C., Ito, Y. et al. (2018). Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol 92, 2043-2054. doi:10.1007/s00204-018-2199-7

Klug, Y. A., Schwarzer, R., Rotem, E. et al. (2019). The HIV gp41 fusion protein inhibits T-cell activation through the Lentiviral lytic peptide 2 motif. Biochemistry 58, 818-832.
Morgan, C. D., Greene, J. F. Jr., Measel, J. W. Jr. (1999). Induction of surface antigen CD54 expression by activation of non-sensitizers upregulate CD69 expression by activation of nickel. *J Investig Allergol Clin Immunol* 29, 287-293. doi:10.1016/j.jaci.0331

Lee, E., Ahn, S., Jin, S. H. et al. (2020). CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. *Toxicol Appl Pharmacol* 386, 114828. doi:10.1016/j.taap.2019.114828

Lim, Y. M., Moon, S. J., An, S. S. et al. (2008). Suitability of macrophage inflammatory protein-1β production by THP-1 cells in differentiating skin sensitizers from irritant chemicals. *Contact Dermatitis* 58, 193-198. doi:10.1111/j.1600-0536.2007.01311.x

Loveless, S. E., Api, A. M., Crevel, R. W. et al. (2010). Potency values from the local lymph node assay: Application to classification, labelling and risk assessment. *Regul Toxicol Pharmacol* 56, 54-66. doi:10.1016/j.yrtph.2009.08.016

Marigliani, B., Silva, J. V. M. A., Balottin, L. B. L. et al. (2019). Adaptation of a skin sensitization assay to a chemically defined culture. *Toxicol In Vitro* 57, 145-153. doi:10.1016/j.tiv.2018.12.004

Mitachi, T., Kouzui, M., Maruyama, R. et al. (2019). Some non-sensitizers upregulate CD54 expression by activation of the NLRP3 inflammasome in THP-1 cells. *J Toxicol Sci* 44, 213-224. doi:10.2131/jts.44.213

Morgan, C. D., Greene, J. F. Jr., Measel, J. W. Jr. (1999). Induction of surface antigen CD69 expression in T-lymphocytes following exposure to actinomycin D. *Int J Immunopharmacol* 21, 689-703. doi:10.1016/S0191-0561(99)00454-7

Natsch, A. and Haupt, T. (2013). Utility of rat liver S9 fractions to study skin-sensitizing prohaptons in a modified Keratinosens assay. *Toxicol Sci* 135, 356-368. doi:10.1093/toxsci/kft160

Natsch, A., Ryan, C. A., Foertsch, L. et al. (2013). A dataset on 145 chemicals tested in alternative assays for skin sensitization undergoing prevalidation. *J Appl Toxicol* 33, 1337-1352. doi:10.1002/jat.2868

Ngo, Q. T., Lee, H. S., Nguyen, V. T. et al. (2017). Chemical constituents from the fruits of Ligustrum japonicum and their inhibitory effects on T cell activation. *Phytochemistry* 141, 147-155. doi:10.1016/j.phytochem.2017.06.001

Nukada, Y., Ashikaga, T., Miyazawa, M. et al. (2012). Prediction of skin sensitization potency of chemicals by human cell line activation test (h-CLAT) and an attempt at classifying skin sensitization potency. *Toxicol In Vitro* 26, 1150-1160. doi:10.1016/j.tiv.2012.07.001

Nukada, Y., Miyazawa, M., Kazutoshi, S. et al. (2013). Data integration of non-animal tests for the development of a test battery to predict the skin-sensitizing potential and potency of chemicals. *Toxicol In Vitro* 27, 609-618. doi:10.1016/j.tiv.2012.11.006

OECD (1992). Test No. 406: Skin Sensitisation. *OECD Guidelines for the Testing of Chemicals, Section 4*. OECD Publishing, Paris. doi:10.1787/9789264070660-en

OECD (2010a). Test No. 429: Skin Sensitisation: Local Lymph Node Assay. *OECD Guidelines for the Testing of Chemicals, Section 4*. OECD Publishing, Paris. doi:10.1787/9789264090972-en

OECD (2010b). Test No. 442A: Skin Sensitization: Local Lymph Node Assay: DA. *OECD Guidelines for the Testing of Chemicals, Section 4*. OECD Publishing, Paris. doi:10.1787/9789264090996-en

OECD (2012). The Adverse Outcome Pathway for Skin Sensitisation Initiated by Covalent Binding to Proteins. *OECD Series on Testing and Assessment, No. 168*. OECD Publishing, Paris. doi:10.1787/9789264221444-en

OECD (2015a). Test No. 442C: In Chemico Skin Sensitisation: Direct Peptide Reactivity Assay (DPRA). *OECD Guidelines for the Testing of Chemicals, Section 4*. OECD Publishing, Paris. doi:10.1787/9789264229709-en

OECD (2015b). Test No. 442D: In Vitro Skin Sensitisation: ARE-Nrf2 Luciferase Test Method. *OECD Guidelines for the Testing of Chemicals, Section 4*. OECD Publishing, Paris. doi:10.1787/9789264229822-en

OECD (2016). Guidance Document on the Reporting of Defined Approaches and Individual Information Sources to be Used within Integrated Approaches to Testing and Assessment (IATA) for Skin Sensitisation. *OECD Series on Testing and Assessment, No. 256*. OECD Publishing, Paris. doi:10.1787/9789264279285-en

OECD (2018). Test No. 442E: In Vitro Skin Sensitization Assays Addressing the Key Event on Activation of Dendritic Cells on the Adverse Outcome Pathway for Skin Sensitization. *OECD Guidelines for the Testing of Chemicals, Section 4*. OECD Publishing, Paris. doi:10.1787/9789264264359-en

Pan, Y., Wei, X. and Hao, W. (2015). Trichloroethylene and its oxidative metabolites enhance the activated state and Th1 cytokine gene expression in Jurkat cells. *Int J Environ Res Public Health* 12, 145-153. doi:10.3390/ijerph120910575

Patlewicz, G., Casati, S., Baskett, D. A. et al. (2016). Can currently available non-animal methods detect pre and pro-haptons relevant for skin sensitization? *Regul Toxicol Pharmacol* 82, 147-155. doi:10.1016/j.yrtph.2016.08.007

Piroird, C., Ovigne, J. M., Rousset, F. et al. (2015). The myeloid dendritic cell event in the adverse outcome pathway for skin sensitization. *Toxicol In Vitro* 29, 901-916. doi:10.1016/j.tiv.2015.03.009

Reisinger, K., Hoffmann, S., Alepee, N. et al. (2015). Systematic evaluation of non-animal test methods for skin sensitisation safety assessment. *Toxicol In Vitro* 29, 259-270. doi:10.1016/j.tiv.2014.10.018

Richter, A., Schmucker, S. S., Esser, P. R. et al. (2013). Hu-
man T cell priming assay (hTCPA) for the identification of contact allergens based on naive T cells and DC – IFN-γ and TNF-α readout. *Toxicol In Vitro* 27, 1180-1185. doi:10.1016/j.tiv.2012.08.007

Robey, E. and Allison, J. P. (1995). T-cell activation: Integration of signals from the antigen receptor and costimulatory molecules. *Immunol Today* 16, 306-310. doi:10.1016/0167-5699(95)80140-5

Sens-it-iv list (2009). http://chelist.jrc.ec.europa.eu/index.jsp?id=2&id_list=26

Strickland, J., Zang, Q., Kleinstreuer, N. et al. (2016). Integrated decision strategies for skin sensitization hazard. *J Appl Toxicol* 36, 1150-1162. doi:10.1002/jat.3281

Swirski, F. K., Gajewska, B. U., Alvarez, D. et al. (2002). Inhalation of a harmless antigen (ovalbumin) elicits immune activation but divergent immunoglobulin and cytokine activities in mice. *Clin Exp Allergy* 32, 411-421. doi:10.1046/j.1365-2222.2002.01291.x

Takahashi, T., Kimura, Y., Saito, R. et al. (2011). An in vitro test to screen skin sensitizers using a stable THP-1-derived IL-8 reporter cell line, THP-G8. *Toxicol Sci* 124, 359-369. doi:10.1093/toxsci/kfr237

Taylor-Fishwick, D. A. and Siegel, J. N. (1995). Raf-1 provides a dominant but not exclusive signal for the induction of CD69 expression on T cells. *Eur J Immunol* 25, 3215-3221. doi:10.1002/eji.1830251203

Testi, R., Phillips, J. H. and Lanier, L. L. (1989). Leu 23 induction as an early marker of functional CD3/T cell antigen receptor triggering: Requirement for receptor cross-linking, prolonged elevation of intracellular [Ca++] and stimulation of protein kinase C. *J Immunol* 142, 1854-1860.

Urbisch, D., Becker, M., Honarvar, N. et al. (2016). Assessment of pre- and pro-haptens using nonanimal test methods for skin sensitization. *Chem Res Toxicol* 29, 901-913. doi:10.1021/acs.chemrestox.6b00055

van Vliet, E., Kühnl, J., Goebel, C. et al. (2018). State-of-the-art and new options to assess T cell activation by skin sensitizers: Cosmetics Europe Workshop. *ALTEX* 35, 179-192. doi:10.14573/altex.1709011

Vis, B., Hewitt, R. E., Faria, N. et al. (2018). Non-functionalized ultrasmall silica nanoparticles directly and size-selectively activate T cells. *ACS Nano* 12, 10843-10854. doi:10.1021/acsnano.8b03363

Vocanson, M., Achachi, A., Mutez, V. et al. (2014). Human T cell priming assay: Depletion of peripheral blood lymphocytes in CD25+ cells improves the in vitro detection of weak allergen-specific T cells. *Exp Suppl* 104, 89-100. doi:10.1007/978-3-0348-0726-5_7

Zahid, S., Mustafa, A., Dina, A. et al. (2019). Nickel challenge up regulates CD69 expression on T lymphocyte sub-sets from patients with nickel induced contact dermatitis. *Afr Health Sci* 19, 1460-1466. doi:10.4314/ahs.v19i1.19

Ziegler, S. F., Ramsdell, F. and Alderson, M. R. (1994). The activation antigen CD69. *Stem Cells* 12, 456-465. doi:10.1002/stem.5530120502

**Conflict of interest**

The authors declare that there are no conflicts of interest.

**Acknowledgements**

This research was sponsored and funded by the National Institute of Occupational Health and Poison Control, Chinese Center for Disease Control and Prevention in 2019 (grant number:19.1.3.1).